{"id":7328,"date":"2025-01-28T08:30:00","date_gmt":"2025-01-28T07:30:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/"},"modified":"2025-01-28T08:30:00","modified_gmt":"2025-01-28T07:30:00","slug":"nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/","title":{"rendered":"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp"},"content":{"rendered":"
\n

Nanexa AB meddelar att fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid, \u00e5terupptas med ytterligare doseskalering med ber\u00e4knad start under f\u00f6rsta kvartalet 2025. Studien har nu f\u00e5tt myndighetsgodk\u00e4nnande att inkludera patienter till en ytterligare dosgrupp f\u00f6r administrering av 30 mg liraglutid.<\/strong><\/p>\n<\/div>\n

\n

Studien genomf\u00f6rs, som tidigare, p\u00e5 patienter med typ 2-diabetes, som inte tidigare behandlats med GLP-1-l\u00e4kemedel, p\u00e5 Profil, ett v\u00e4rldsledande diabetes-CRO i Tyskland. Studien har som meddelats i november slutf\u00f6rt tre kohorter med eskalerande doser upp till 10 mg i syfte att bed\u00f6ma den farmakokinetiska profilen, s\u00e4kerheten och tolerabiliteten f\u00f6r olika dosniv\u00e5er. Dep\u00e5formuleringen NEX-22 administreras som en injektion under huden (subkutant). Resultat fr\u00e5n en fj\u00e4rde kohort ber\u00e4knas under andra kvartalet 2025.<\/p>\n

"Att l\u00e4gga till en ytterligare dosgrupp ger oss en m\u00f6jlighet att redan nu studera en formulering av NEX-22 i en betydligt h\u00f6gre dos. Denna doseskalering kommer ge oss ytterligare grund f\u00f6r n\u00e4stkommande fas Ib\/II studie och vidareutveckling av NEX-22", s\u00e4ger David Westberg, VD f\u00f6r Nanexa.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB meddelar att fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid, \u00e5terupptas med ytterligare doseskalering med ber\u00e4knad start under f\u00f6rsta kvartalet 2025. Studien har nu f\u00e5tt myndighetsgodk\u00e4nnande att inkludera patienter till en ytterligare dosgrupp f\u00f6r administrering av 30 mg liraglutid.<\/p>\n","protected":false},"template":"","class_list":["post-7328","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB meddelar att fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid, \u00e5terupptas med ytterligare doseskalering med ber\u00e4knad start under f\u00f6rsta kvartalet 2025. Studien har nu f\u00e5tt myndighetsgodk\u00e4nnande att inkludera patienter till en ytterligare dosgrupp f\u00f6r administrering av 30 mg liraglutid.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\\\/\",\"name\":\"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2025-01-28T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp - Nanexa AB","og_description":"Nanexa AB meddelar att fas I-studien med NEX-22, bolagets enm\u00e5nadsformulering av liraglutid, \u00e5terupptas med ytterligare doseskalering med ber\u00e4knad start under f\u00f6rsta kvartalet 2025. Studien har nu f\u00e5tt myndighetsgodk\u00e4nnande att inkludera patienter till en ytterligare dosgrupp f\u00f6r administrering av 30 mg liraglutid.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/","name":"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2025-01-28T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-expanderar-fas-i-studien-med-nex-22-med-ytterligare-en-dosgrupp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa expanderar fas I-studien med NEX-22 med ytterligare en dosgrupp"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}